Dicerna制药

DRNA NASDAQ
13.05
-0.51
-3.76%
盘后: 13.05 0 0.00% 16:29 08/22 EDT
开盘
13.69
昨收
13.56
最高
13.73
最低
12.91
成交量
58.37万
成交均量(3M)
41.09万
52周最高
17.98
52周最低
9.31
换手率
0.81%
市值
8.92亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Dicerna制药 DRNA股票价格,Dicerna制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
展开 >

最近浏览

名称
价格
涨跌幅